Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8LBYT)

Drug Name

NIS793 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Pancreatic ductal carcinoma	2C10.0	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Transforming growth factor beta (TGFB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
M7824	DMJCULI	Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
TEW-7197	DM2LBC3	Myeloproliferative neoplasm	2A20	Phase 2	[2]
Bintrafusp alfa	DMB9LRJ	Non-small-cell lung cancer	2C25	Phase 2	[3]
LY2382770	DMH3YKJ	Diabetic kidney disease	GB61.Z	Phase 2	[4]
Fresolimumab	DMFZ084	Brain cancer	2A00	Phase 2	[5]
BCA101	DMM0VBU	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
GS-1423	DMS25DL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
ACE-011	DMJ36YH	Anemia	3A00-3A9Z	Phase 1	[8]
AVID200	DMZ39T6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
RG6440	DMVQXFH	Aggressive cancer	2A00-2F9Z	Phase 1	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Transforming growth factor beta (TGFB)	TTO3HT7	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04390763) Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222.
4	A phase I dose-escalation study to a predefined dose of a transforming growth factor-1 monoclonal antibody (TM1) in patients with metastatic cancer. Int J Oncol. 2014 Dec;45(6):2221-31.
5	Focal Irradiation and Systemic TGF Blockade in Metastatic Breast Cancer. Clin Cancer Res. 2018 Jun 1;24(11):2493-2504.
6	ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health.
7	Clinical pipeline report, company report or official report of Agenus.
8	Clinical pipeline report, company report or official report of Acceleron Pharma (2011).
9	TGF signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond Syndrome. J Clin Invest. 2019 Jun 18;129(9):3821-3826.
10	Clinical pipeline report, company report or official report of Roche